Camlin Fine Sciences Q2 Review - Below Estimate Performance: Nirmal Bang

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Nirmal Bang Report.Camlin Fine Sciences Ltd.’s Q2 FY22 consolidated Ebitda came 56% below our estimate mainly on account of disruption in supply chain and logistics and production impact in products like TBHQ, BHA, MEHQ etc. due to technical issues faced while scaling up the Diphenol plant at Dahej. Ebitda adjusted for one-offs related to production loss and supply chain disruption (Rs 125 million) and non-recurring expense (Rs 35 million) was down ~15% QoQ. Camlin Fine Sciences expects H2 FY22 to be better given that the production-related challenges are behind and is confident of pass-through of raw material inflation impact (in HQ chain) with a one quarter lag. Also, almost 70-80% of the clients have agreed to shift to freight on board basis in the coming quarters, which will reduce the cost impact in case of freight. .Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Camlin Fine Sciences Q2 Review - Below Estimate Performance: Nirmal Bang

Camlin Fine Sciences Q2 Review - Below Estimate Performance: Nirmal Bang

Choose a plan